Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67


A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity.

York J, Nunberg JH.

Methods Mol Biol. 2018;1604:157-167. doi: 10.1007/978-1-4939-6981-4_10.


Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization.

Zeltina A, Krumm SA, Sahin M, Struwe WB, Harlos K, Nunberg JH, Crispin M, Pinschewer DD, Doores KJ, Bowden TA.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7031-7036. doi: 10.1073/pnas.1702127114. Epub 2017 Jun 19.


Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein.

Shankar S, Whitby LR, Casquilho-Gray HE, York J, Boger DL, Nunberg JH.

J Virol. 2016 Jul 11;90(15):6799-807. doi: 10.1128/JVI.00597-16. Print 2016 Aug 1.


Biochemical reconstitution of hemorrhagic-fever arenavirus envelope glycoprotein-mediated membrane fusion.

Thomas CJ, Shankar S, Casquilho-Gray HE, York J, Sprang SR, Nunberg JH.

PLoS One. 2012;7(11):e51114. doi: 10.1371/journal.pone.0051114. Epub 2012 Nov 30.


Arenavirus infection induces discrete cytosolic structures for RNA replication.

Baird NL, York J, Nunberg JH.

J Virol. 2012 Oct;86(20):11301-10. Epub 2012 Aug 8. Erratum in: J Virol. 2013 Mar;87(5):2983.


Dissection of the role of the stable signal peptide of the arenavirus envelope glycoprotein in membrane fusion.

Messina EL, York J, Nunberg JH.

J Virol. 2012 Jun;86(11):6138-45. doi: 10.1128/JVI.07241-11. Epub 2012 Mar 21.


The curious case of arenavirus entry, and its inhibition.

Nunberg JH, York J.

Viruses. 2012 Jan;4(1):83-101. doi: 10.3390/v4010083. Epub 2012 Jan 13. Review.


A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus.

Thomas CJ, Casquilho-Gray HE, York J, DeCamp DL, Dai D, Petrilli EB, Boger DL, Slayden RA, Amberg SM, Sprang SR, Nunberg JH.

J Biol Chem. 2011 Feb 25;286(8):6192-200. doi: 10.1074/jbc.M110.196428. Epub 2010 Dec 15.


T-705 (favipiravir) inhibition of arenavirus replication in cell culture.

Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB.

Antimicrob Agents Chemother. 2011 Feb;55(2):782-7. doi: 10.1128/AAC.01219-10. Epub 2010 Nov 29.


Structure of a zinc-binding domain in the Junin virus envelope glycoprotein.

Briknarová K, Thomas CJ, York J, Nunberg JH.

J Biol Chem. 2011 Jan 14;286(2):1528-36. doi: 10.1074/jbc.M110.166025. Epub 2010 Nov 10.


An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.

York J, Berry JD, Ströher U, Li Q, Feldmann H, Lu M, Trahey M, Nunberg JH.

J Virol. 2010 Jun;84(12):6119-29. doi: 10.1128/JVI.02700-09. Epub 2010 Apr 14.


Assembly of arenavirus envelope glycoprotein GPC in detergent-soluble membrane microdomains.

Agnihothram SS, Dancho B, Grant KW, Grimes ML, Lyles DS, Nunberg JH.

J Virol. 2009 Oct;83(19):9890-900. doi: 10.1128/JVI.00837-09. Epub 2009 Jul 22.


Intersubunit interactions modulate pH-induced activation of membrane fusion by the Junin virus envelope glycoprotein GPC.

York J, Nunberg JH.

J Virol. 2009 May;83(9):4121-6. doi: 10.1128/JVI.02410-08. Epub 2009 Feb 18.


pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors.

York J, Dai D, Amberg SM, Nunberg JH.

J Virol. 2008 Nov;82(21):10932-9. doi: 10.1128/JVI.01140-08. Epub 2008 Sep 3.


Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses.

Lee AM, Rojek JM, Spiropoulou CF, Gundersen AT, Jin W, Shaginian A, York J, Nunberg JH, Boger DL, Oldstone MB, Kunz S.

J Biol Chem. 2008 Jul 4;283(27):18734-42. doi: 10.1074/jbc.M802089200. Epub 2008 May 12.


Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses.

Radoshitzky SR, Abraham J, Spiropoulou CF, Kuhn JH, Nguyen D, Li W, Nagel J, Schmidt PJ, Nunberg JH, Andrews NC, Farzan M, Choe H.

Nature. 2007 Mar 1;446(7131):92-6. Epub 2007 Feb 7.


Bitopic membrane topology of the stable signal peptide in the tripartite Junín virus GP-C envelope glycoprotein complex.

Agnihothram SS, York J, Trahey M, Nunberg JH.

J Virol. 2007 Apr;81(8):4331-7. Epub 2007 Jan 31.


Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein.

Nakai K, Okamoto T, Kimura-Someya T, Ishii K, Lim CK, Tani H, Matsuo E, Abe T, Mori Y, Suzuki T, Miyamura T, Nunberg JH, Moriishi K, Matsuura Y.

J Virol. 2006 Nov;80(22):11265-73. Epub 2006 Sep 13.


Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry.

Follis KE, York J, Nunberg JH.

Virology. 2006 Jul 5;350(2):358-69. Epub 2006 Mar 7.


Genetic analysis of heptad-repeat regions in the G2 fusion subunit of the Junín arenavirus envelope glycoprotein.

York J, Agnihothram SS, Romanowski V, Nunberg JH.

Virology. 2005 Dec 20;343(2):267-74. Epub 2005 Sep 16.


Evidence for a polytopic form of the E1 envelope glycoprotein of Hepatitis C virus.

Migliaccio CT, Follis KE, Matsuura Y, Nunberg JH.

Virus Res. 2004 Sep 15;105(1):47-57.


Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion.

Wang S, York J, Shu W, Stoller MO, Nunberg JH, Lu M.

Biochemistry. 2002 Jun 11;41(23):7283-92.



Nunberg JH.

Science. 2002 May 10;296(5570):1025. No abstract available.


Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

York J, Follis KE, Trahey M, Nyambi PN, Zolla-Pazner S, Nunberg JH.

J Virol. 2001 Mar;75(6):2741-52.


Turning a corner on HIV neutralization?

Nunberg JH, Follis KE, Trahey M, LaCasse RA.

Microbes Infect. 2000 Feb;2(2):213-21. Review.


Fusion-competent vaccines: broad neutralization of primary isolates of HIV.

LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH.

Science. 1999 Jan 15;283(5400):357-62. Retraction in: Nunberg JH. Science. 2002 May 10;296(5570):1025.


Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.

LaCasse RA, Follis KE, Moudgil T, Trahey M, Binley JM, Planelles V, Zolla-Pazner S, Nunberg JH.

J Virol. 1998 Mar;72(3):2491-5.


Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25.

Quakyi IA, Miller LH, Good MF, Ahlers JD, Isaacs SN, Nunberg JH, Houghten RA, Keister DB, Coligan JE, Moss B, et al.

Pept Res. 1995 Nov-Dec;8(6):335-44.


Development of a single-shot subunit vaccine for HIV-1.

Cleland JL, Powell MF, Lim A, Barrón L, Berman PW, Eastman DJ, Nunberg JH, Wrin T, Vennari JC.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S21-6.


Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .

Powell MF, Cleland JL, Eastman DJ, Lim A, Murthy K, Newman MJ, Nunberg JH, Weissburg RP, Vennari JC, Wrin T, et al.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S105-8. Erratum in: AIDS Res Hum Retroviruses 1995 May;11(5):661.


L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.

Goldman ME, O'Brien JA, Ruffing TL, Nunberg JH, Schleif WA, Quintero JC, Siegl PK, Hoffman JM, Smith AM, Emini EA.

Antimicrob Agents Chemother. 1992 May;36(5):1019-23.


Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, et al.

Nature. 1992 Feb 20;355(6362):728-30.


2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.

Saari WS, Hoffman JM, Wai JS, Fisher TE, Rooney CS, Smith AM, Thomas CM, Goldman ME, O'Brien JA, Nunberg JH, et al.

J Med Chem. 1991 Sep;34(9):2922-5. No abstract available.


Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.

Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, Emini EA, Goldman ME.

J Virol. 1991 Sep;65(9):4887-92.


Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.

Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, et al.

Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6863-7.

Supplemental Content

Loading ...
Support Center